Wugen has raised $115 million led by Fidelity Management & Research to fund pivotal trials for WU-CART-007, its allogeneic CAR-T therapy for relapsed or refractory T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma. The off-the-shelf therapy, using donor cells, aims to offer a convenient alternative to autologous CAR-T approaches. Wugen plans approval filings in 2027 contingent on trial success, positioning itself at the forefront of cell therapy innovation for T-cell cancers.